bestseller

Global Radiopharmaceutical Market Growth 2023-2029

Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic

Region : 010411310648 | Price: 2900 | Report ID: 010411310648
Radiopharmaceuticals are radioactive compounds administered to the patient, and monitored via specific imaging devices, for diagnosis and therapeutic purposes. It is composed of a radioisotope bond to an organic molecule. The organic molecule conveys the radioisotope to specific organs, tissues or cells. The radioisotope is selected for its properties. Radiopharmaceuticals are used in the field of nuclear medicine as radioactive tracers in medical imaging and in therapy for many diseases (for example, brachytherapy). Many radiopharmaceuticals use technetium-99m (Tc-99m) which has many useful properties as a gamma-emitting tracer nuclide.
LPI (LP Information)' newest research report, the “Radiopharmaceutical Industry Forecast” looks at past sales and reviews total world Radiopharmaceutical sales in 2022, providing a comprehensive analysis by region and market sector of projected Radiopharmaceutical sales for 2023 through 2029. With Radiopharmaceutical sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Radiopharmaceutical industry.
This Insight Report provides a comprehensive analysis of the global Radiopharmaceutical landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyzes the strategies of leading global companies with a focus on Radiopharmaceutical portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms' unique position in an accelerating global Radiopharmaceutical market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Radiopharmaceutical and breaks down the forecast by type, by application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Radiopharmaceutical.
The global Radiopharmaceutical market size is projected to grow from US$ 6613.9 million in 2022 to US$ 11560 million in 2029; it is expected to grow at a CAGR of 11560 from 2023 to 2029.
The global Radiopharmaceutical top three manufacturers include the Bracco Imaging, Bayer and Mallinckrodt, with about 47% market shares. North America and Europe is the main consumption places, with a consumption market share nearly 45% and 27%.
This report presents a comprehensive overview, market shares, and growth opportunities of Radiopharmaceutical market by product type, application, key manufacturers and key regions and countries.
Market Segmentation:
Segmentation by type
Actinium-225
Lutetium-177
Radium-223
Holmium-166
Other
Segmentation by application
Oncology
Cardiology
Other
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bracco Imaging
Bayer
Mallinckrodt
Nordion
Triad Isotopes
Lantheus
IBA Group
GE Healthcare
China Isotope & Radiation
Jubilant Pharma
Eli Lilly
Advanced Accelerator Applications
SIEMENS
Dongcheng
Navidea
Key Questions Addressed in this Report
What is the 10-year outlook for the global Radiopharmaceutical market?
What factors are driving Radiopharmaceutical market growth, globally and by region?
Which technologies are poised for the fastest growth by market and region?
How do Radiopharmaceutical market opportunities vary by end market size?
How does Radiopharmaceutical break out type, application?
What are the influences of COVID-19 and Russia-Ukraine war?
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Radiopharmaceutical Annual Sales 2018-2029
2.1.2 World Current & Future Analysis for Radiopharmaceutical by Geographic Region, 2018, 2022 & 2029
2.1.3 World Current & Future Analysis for Radiopharmaceutical by Country/Region, 2018, 2022 & 2029
2.2 Radiopharmaceutical Segment by Type
2.2.1 Actinium-225
2.2.2 Lutetium-177
2.2.3 Radium-223
2.2.4 Holmium-166
2.2.5 Other
2.3 Radiopharmaceutical Sales by Type
2.3.1 Global Radiopharmaceutical Sales Market Share by Type (2018-2023)
2.3.2 Global Radiopharmaceutical Revenue and Market Share by Type (2018-2023)
2.3.3 Global Radiopharmaceutical Sale Price by Type (2018-2023)
2.4 Radiopharmaceutical Segment by Application
2.4.1 Oncology
2.4.2 Cardiology
2.4.3 Other
2.5 Radiopharmaceutical Sales by Application
2.5.1 Global Radiopharmaceutical Sale Market Share by Application (2018-2023)
2.5.2 Global Radiopharmaceutical Revenue and Market Share by Application (2018-2023)
2.5.3 Global Radiopharmaceutical Sale Price by Application (2018-2023)
3 Global Radiopharmaceutical by Company
3.1 Global Radiopharmaceutical Breakdown Data by Company
3.1.1 Global Radiopharmaceutical Annual Sales by Company (2018-2023)
3.1.2 Global Radiopharmaceutical Sales Market Share by Company (2018-2023)
3.2 Global Radiopharmaceutical Annual Revenue by Company (2018-2023)
3.2.1 Global Radiopharmaceutical Revenue by Company (2018-2023)
3.2.2 Global Radiopharmaceutical Revenue Market Share by Company (2018-2023)
3.3 Global Radiopharmaceutical Sale Price by Company
3.4 Key Manufacturers Radiopharmaceutical Producing Area Distribution, Sales Area, Product Type
3.4.1 Key Manufacturers Radiopharmaceutical Product Location Distribution
3.4.2 Players Radiopharmaceutical Products Offered
3.5 Market Concentration Rate Analysis
3.5.1 Competition Landscape Analysis
3.5.2 Concentration Ratio (CR3, CR5 and CR10) & (2018-2023)
3.6 New Products and Potential Entrants
3.7 Mergers & Acquisitions, Expansion
4 World Historic Review for Radiopharmaceutical by Geographic Region
4.1 World Historic Radiopharmaceutical Market Size by Geographic Region (2018-2023)
4.1.1 Global Radiopharmaceutical Annual Sales by Geographic Region (2018-2023)
4.1.2 Global Radiopharmaceutical Annual Revenue by Geographic Region (2018-2023)
4.2 World Historic Radiopharmaceutical Market Size by Country/Region (2018-2023)
4.2.1 Global Radiopharmaceutical Annual Sales by Country/Region (2018-2023)
4.2.2 Global Radiopharmaceutical Annual Revenue by Country/Region (2018-2023)
4.3 Americas Radiopharmaceutical Sales Growth
4.4 APAC Radiopharmaceutical Sales Growth
4.5 Europe Radiopharmaceutical Sales Growth
4.6 Middle East & Africa Radiopharmaceutical Sales Growth
5 Americas
5.1 Americas Radiopharmaceutical Sales by Country
5.1.1 Americas Radiopharmaceutical Sales by Country (2018-2023)
5.1.2 Americas Radiopharmaceutical Revenue by Country (2018-2023)
5.2 Americas Radiopharmaceutical Sales by Type
5.3 Americas Radiopharmaceutical Sales by Application
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Radiopharmaceutical Sales by Region
6.1.1 APAC Radiopharmaceutical Sales by Region (2018-2023)
6.1.2 APAC Radiopharmaceutical Revenue by Region (2018-2023)
6.2 APAC Radiopharmaceutical Sales by Type
6.3 APAC Radiopharmaceutical Sales by Application
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
6.10 China Taiwan
7 Europe
7.1 Europe Radiopharmaceutical by Country
7.1.1 Europe Radiopharmaceutical Sales by Country (2018-2023)
7.1.2 Europe Radiopharmaceutical Revenue by Country (2018-2023)
7.2 Europe Radiopharmaceutical Sales by Type
7.3 Europe Radiopharmaceutical Sales by Application
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Radiopharmaceutical by Country
8.1.1 Middle East & Africa Radiopharmaceutical Sales by Country (2018-2023)
8.1.2 Middle East & Africa Radiopharmaceutical Revenue by Country (2018-2023)
8.2 Middle East & Africa Radiopharmaceutical Sales by Type
8.3 Middle East & Africa Radiopharmaceutical Sales by Application
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Manufacturing Cost Structure Analysis
10.1 Raw Material and Suppliers
10.2 Manufacturing Cost Structure Analysis of Radiopharmaceutical
10.3 Manufacturing Process Analysis of Radiopharmaceutical
10.4 Industry Chain Structure of Radiopharmaceutical
11 Marketing, Distributors and Customer
11.1 Sales Channel
11.1.1 Direct Channels
11.1.2 Indirect Channels
11.2 Radiopharmaceutical Distributors
11.3 Radiopharmaceutical Customer
12 World Forecast Review for Radiopharmaceutical by Geographic Region
12.1 Global Radiopharmaceutical Market Size Forecast by Region
12.1.1 Global Radiopharmaceutical Forecast by Region (2024-2029)
12.1.2 Global Radiopharmaceutical Annual Revenue Forecast by Region (2024-2029)
12.2 Americas Forecast by Country
12.3 APAC Forecast by Region
12.4 Europe Forecast by Country
12.5 Middle East & Africa Forecast by Country
12.6 Global Radiopharmaceutical Forecast by Type
12.7 Global Radiopharmaceutical Forecast by Application
13 Key Players Analysis
13.1 Bracco Imaging
13.1.1 Bracco Imaging Company Information
13.1.2 Bracco Imaging Radiopharmaceutical Product Portfolios and Specifications
13.1.3 Bracco Imaging Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.1.4 Bracco Imaging Main Business Overview
13.1.5 Bracco Imaging Latest Developments
13.2 Bayer
13.2.1 Bayer Company Information
13.2.2 Bayer Radiopharmaceutical Product Portfolios and Specifications
13.2.3 Bayer Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.2.4 Bayer Main Business Overview
13.2.5 Bayer Latest Developments
13.3 Mallinckrodt
13.3.1 Mallinckrodt Company Information
13.3.2 Mallinckrodt Radiopharmaceutical Product Portfolios and Specifications
13.3.3 Mallinckrodt Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.3.4 Mallinckrodt Main Business Overview
13.3.5 Mallinckrodt Latest Developments
13.4 Nordion
13.4.1 Nordion Company Information
13.4.2 Nordion Radiopharmaceutical Product Portfolios and Specifications
13.4.3 Nordion Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.4.4 Nordion Main Business Overview
13.4.5 Nordion Latest Developments
13.5 Triad Isotopes
13.5.1 Triad Isotopes Company Information
13.5.2 Triad Isotopes Radiopharmaceutical Product Portfolios and Specifications
13.5.3 Triad Isotopes Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.5.4 Triad Isotopes Main Business Overview
13.5.5 Triad Isotopes Latest Developments
13.6 Lantheus
13.6.1 Lantheus Company Information
13.6.2 Lantheus Radiopharmaceutical Product Portfolios and Specifications
13.6.3 Lantheus Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.6.4 Lantheus Main Business Overview
13.6.5 Lantheus Latest Developments
13.7 IBA Group
13.7.1 IBA Group Company Information
13.7.2 IBA Group Radiopharmaceutical Product Portfolios and Specifications
13.7.3 IBA Group Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.7.4 IBA Group Main Business Overview
13.7.5 IBA Group Latest Developments
13.8 GE Healthcare
13.8.1 GE Healthcare Company Information
13.8.2 GE Healthcare Radiopharmaceutical Product Portfolios and Specifications
13.8.3 GE Healthcare Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.8.4 GE Healthcare Main Business Overview
13.8.5 GE Healthcare Latest Developments
13.9 China Isotope & Radiation
13.9.1 China Isotope & Radiation Company Information
13.9.2 China Isotope & Radiation Radiopharmaceutical Product Portfolios and Specifications
13.9.3 China Isotope & Radiation Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.9.4 China Isotope & Radiation Main Business Overview
13.9.5 China Isotope & Radiation Latest Developments
13.10 Jubilant Pharma
13.10.1 Jubilant Pharma Company Information
13.10.2 Jubilant Pharma Radiopharmaceutical Product Portfolios and Specifications
13.10.3 Jubilant Pharma Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.10.4 Jubilant Pharma Main Business Overview
13.10.5 Jubilant Pharma Latest Developments
13.11 Eli Lilly
13.11.1 Eli Lilly Company Information
13.11.2 Eli Lilly Radiopharmaceutical Product Portfolios and Specifications
13.11.3 Eli Lilly Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.11.4 Eli Lilly Main Business Overview
13.11.5 Eli Lilly Latest Developments
13.12 Advanced Accelerator Applications
13.12.1 Advanced Accelerator Applications Company Information
13.12.2 Advanced Accelerator Applications Radiopharmaceutical Product Portfolios and Specifications
13.12.3 Advanced Accelerator Applications Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.12.4 Advanced Accelerator Applications Main Business Overview
13.12.5 Advanced Accelerator Applications Latest Developments
13.13 SIEMENS
13.13.1 SIEMENS Company Information
13.13.2 SIEMENS Radiopharmaceutical Product Portfolios and Specifications
13.13.3 SIEMENS Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.13.4 SIEMENS Main Business Overview
13.13.5 SIEMENS Latest Developments
13.14 Dongcheng
13.14.1 Dongcheng Company Information
13.14.2 Dongcheng Radiopharmaceutical Product Portfolios and Specifications
13.14.3 Dongcheng Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.14.4 Dongcheng Main Business Overview
13.14.5 Dongcheng Latest Developments
13.15 Navidea
13.15.1 Navidea Company Information
13.15.2 Navidea Radiopharmaceutical Product Portfolios and Specifications
13.15.3 Navidea Radiopharmaceutical Sales, Revenue, Price and Gross Margin (2018-2023)
13.15.4 Navidea Main Business Overview
13.15.5 Navidea Latest Developments
14 Research Findings and Conclusion

 

Research Methodology

 

SECONDARY RESEARCH
Secondary Research Information is collected from a number of publicly available as well as paid databases. Public sources involve publications by different associations and governments, annual reports and statements of companies, white papers and research publications by recognized industry experts and renowned academia etc. Paid data sources include third party authentic industry databases.

PRIMARY RESEARCH
Once data collection is done through secondary research, primary interviews are conducted with different stakeholders across the value chain like manufacturers, distributors, ingredient/input suppliers, end customers and other key opinion leaders of the industry. Primary research is used both to validate the data points obtained from secondary research and to fill in the data gaps after secondary research.

MARKET ENGINEERING
The market engineering phase involves analysing the data collected, market breakdown and forecasting. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights. Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.

EXPERT VALIDATION
The market engineered data is verified and validated by a number of experts, both in-house and external.

REPORT WRITING/ PRESENTATION
After the data is curated by the mentioned highly sophisticated process, the analysts begin to write the report. Garnering insights from data and forecasts, insights are drawn to visualize the entire ecosystem in a single report.